Compare Erajaya Swasembada Tbk. (ERAA) vs Organon Pharma Indonesia Tbk. (SCPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Erajaya Swasembada Tbk. vs Organon Pharma Indonesia Tbk. — how do they compare? Erajaya Swasembada Tbk. trades at Rp595 (market cap 9.41T, 91.64M 24h volume), while Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B). The key difference: Erajaya Swasembada Tbk. is far larger — about 90.1× Organon Pharma Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.
| ERAA | SCPI | |
|---|---|---|
Market Cap | 9.41T | 104.4B |
Volume | 91.64M | — |
Lot | 916.38K | — |
Turnover | 53.7B | — |
Average Price | 585.95 | — |
Value | 53.7B | — |
Indicative Equilibrium Price | 595 | — |
Indicative Equilibrium Volume | 32.64K | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Erajaya Swasembada Tbk.
PT Erajaya Swasembada Tbk (the Company) was established in Jakarta based on Notarial Deed No.7 of Myra Yuwono, S.H., dated October 8, 1996. Erajaya Group is the official distributor for 10 international mobile communication brands and an authorised partner for major mobile operators. Recently, the Group has launched its own mobile handset under the name of Venera. In 1996, PT Erajaya Swasembada, or Erajaya, the establishment of what we know today as the Erajaya Group, was incorporated.
Read more on ERAA →About Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →
